Erratum: Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma (New England Journal of Medicine (2018) 378 (331-344) DOI: 10.1056/NEJMoa1708984)

In the Abstract (page 331), the first sentence under Results should have begun, "At a median follow-up of 24.6 months," rather than "⋯ 24.9 months," the lower limit of the first confidence interval should have been 78.8, rather than 78.7, and the final P value should have been 0.04, rather than 0.03. In the second sentence, the parenthetical should have read, "(hazard ratio for interim overall survival, 0.73 [95% CI, 0.45 to 1.18]; P = 0.20)," rather than "(hazard ratio⋯, 0.72 [95% CI, 0.44 to 1.17]; P = 0.19)." In the Patients subsection of Results (page 334), the second sentence should have said that 59% of patients had B symptoms, rather than 58%. In the Efficacy subsection of Results (page 334), the first sentence should have begun, "After a median follow-up of 24.6 months (range, 0 to 49.0)", rather than "⋯ 24.9 months (range, 0 to 49.3)." In the same sentence, the lower limit of the first confidence interval should have been 78.8, rather than 78.7, and the final P value should have been P = 0.04, rather than 0.03. In the next paragraph (page 338), the expression "corresponding to a 27% lower overall risk of an event" should have been "⋯ a 28% lower overall risk⋯," and the parenthetical that follows should have read, "(hazard ratio for progression, death, or modified progression, 0.72; 95% CI, 0.57 to 0.91; P = 0.006)," rather than "(⋯ 0.73; 95% CI, 0.57 to 0.92; P = 0.007)." In the same subsection, in the paragraph beginning "There were 28 deaths" (page 339), the second sentence should have read, "The interim 2-year overall survival rate for the A+AVD group was 96.6% (95% CI, 94.8 to 97.7) and that for the ABVD group was 94.2% (95% CI, 92.0 to 95.9), which corresponded to a reduction in the risk of death of 27% in favor of the A+AVD regimen (hazard ratio, 0.73; 95% CI, 0.45 to 1.18; P = 0.20)⋯," rather than "⋯ and that for the ABVD group was 94.9% (95% CI, 92.9 to 96.4), which corresponded to a reduction in the risk of death of 28% in favor of the A+AVD regimen (hazard ratio, 0.72; 95% CI, 0.44 to 1.17; P = 0.19)⋯." In the third paragraph of the Safety subsection of Results (page 340), in the second sentence, beginning "Discussion with⋯," the first parenthetical should have read, "(after 75% of enrollment was complete)," rather than "(after 76%⋯ )." In the first paragraph of the Discussion (page 341), the final sentence should have ended, "and 28% as assessed by the trial investigators," rather than "and 27%⋯." In Table 1 (page 335), there were several errors in the data according to ECOG performance status: in the ECOG score 1 row, the values should have been 260 (39) for A+AVD, 263 (39) for ABVD, and 523 (39) for Total, rather than 259 (39), 262 (39), and 521 (39); in the ECOG score 2 row, the values should have been 27 (4) for ABVD and 55 (4) for Total, rather than 26 (4) and 54 (4); and in the "Not obtained or missing" row, the values should have been 0 for A+AVD, 2 (<1) for ABVD, and 2 (<1) for Total, rather than 1 (<1), 4 (<1), and 5 (<1). In the "Patients with any B symptom" row, the values should have been 400 (60) for A+AVD and 781 (59) for Total, rather than 399 (60) and 780 (58). In Figure 1A (page 336), the P value should have been 0.04, rather than 0.03. In Figure 1B, the hazard ratio should have been 0.72, with an upper confidence limit of 0.91, rather than 0.73 and 0.92, and the P value should have been 0.006, rather than 0.007. The curves in Figure 1 and the data shown in Figure 2 (page 339) have been updated. The article is correct at NEJM.org.